Over the last decade, high-dose chemotherapy (HDC) with autologous stem-cel
l transplantation has been explored for a variety of solid tumors in adults
, particularly breast cancer, ovarian cancer, and nonseminomatous germ-cell
tumors. Response of phase II studies are encouraging in most cases, and, i
n certain settings, seem clearly superior to historical results of conventi
onal-dose chemotherapy. The value of HDC for adult solid tumors is a highly
controversial issue, currently being addressed in large randomized phase I
T trials. This article reviews the results of HDC in different diseases and
depicts potential directions of future progress.